PhoenixBio Co Ltd 6190
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- JPY 492.00
- Day Range
- JPY 484.00–492.00
- 52-Week Range
- JPY 442.00–628.00
- Bid/Ask
- JPY 484.00 / JPY 490.00
- Market Cap
- JPY 1.95 Bil
- Volume/Avg
- 2,000 / 4,543
Key Statistics
- Price/Earnings (Normalized)
- 18.29
- Price/Sales
- 0.99
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics related test, safety test, hepatitis virus (HBV / HCV) related drug efficacy test.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 77
- Website
- http://www.phoenixbio.co.jp
Valuation
|
Metric
|
6190
|
|---|---|
Price/Earnings (Normalized) | 18.29 |
Price/Book Value | 1.10 |
Price/Sales | 0.99 |
Price/Cash Flow | 7.14 |
Price/Earnings
6190
Financial Strength
|
Metric
|
6190
|
|---|---|
Quick Ratio | 3.93 |
Current Ratio | 5.26 |
Interest Coverage | 55.43 |
Quick Ratio
6190
Profitability
|
Metric
|
6190
|
|---|---|
Return on Assets (Normalized) | 3.30% |
Return on Equity (Normalized) | 6.15% |
Return on Invested Capital (Normalized) | 3.86% |
Return on Assets
6190
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bjmghhgch | Lgytnl | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pbtzvrr | Rwyzb | $114.2 Bil | |||
| Moderna Inc
MRNA
| Qwxmkglz | Wyyf | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Mkgpccyyc | Xbtfc | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Krckpcfhc | Ggl | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qdqzmldp | Bpnfw | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lrjlvnv | Bzrrxz | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Hztcwnm | Qyt | $12.8 Bil | |||
| Incyte Corp
INCY
| Mjrmgsbb | Wzxnzv | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Bxgnyqxpxq | Hbvtmp | $12.2 Bil |